Pharmaceuticals
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
Results Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 26, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech Holdings G...
2026-08-26 22:57
5018
Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey MUMBAI, India, Aug. 26, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, today released itsSustainability Re...
2026-08-26 22:49
5130
ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth Disease
Designation supports the global development of RTX-117 and may provide potential future access to a transferable Priority Review Voucher, subject to approval and applicable requirements BRISBANE, Calif., Aug. 26, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company adv...
2026-08-26 21:00
3100
Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
SEATTLE and RICHMOND, BC, Aug. 26, 2026 /PRNewswire/ -- Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's proprietar...
2026-08-26 20:02
2008
SU Group Wins US$2.4 Million Follow-on Award, Expanding Landmark Smart-Hospital Project to US$13.7 Million
Additional Award Broadens the Company's Role in Mission-Critical Healthcare Infrastructure and Strengthens Revenue Visibility HONG KONG, Aug. 26, 2026 /PRNewswire/ -- SU Group Holdings Limited (Nasdaq: SUGP) ("SU Group" or the "Company"), an integrated security-related engineering services compa...
2026-08-26 20:00
3476
Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
* FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide. * U.S. IRB Approval for Pivotal Phase 3 Trial SUPREME-01 (CBL-0301)—The protocol amendment for the pivotal Phase ...
2026-08-26 09:24
1454
/C O R R E C T I O N -- Akeso, Inc./
In the news release, Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline, issued 21-Aug-2026 by Akeso, Inc. over PR Newswire, we are advised by the company that there are some amendments in the "About AK157D1" section. The compl...
2026-08-25 21:15
3409
WuXi Biologics Reports Strong Profitable Growth in H1 2026
* Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD) * IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds * EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY; adjusted...
2026-08-25 20:45
2182
Fosun Pharma Announces 2026 Interim Results
Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the Company r...
2026-08-25 20:44
3271
Innovent Announces 2026 Interim Results and Business Updates
Transforming from Regional Leader to Global Premier: A Clear Strategic Path for Growth and Globalization SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and comm...
2026-08-25 18:15
2490
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
BEIJING, Aug. 25, 2026 /PRNewswire/ -- On August 25, Haisco Pharmaceutical Group Co., Ltd.("Haisco") (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Sentivera, a new US venture founded by Population Health Partners ("PHP") and ARCH Venture Partners (...
2026-08-25 18:14
1567
Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027
TAIPEI, Aug. 25, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombinati...
2026-08-25 14:56
1509
WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
* Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2] basis) * Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit margin was 37.0%, a 0.9 percentage points increas...
2026-08-24 20:35
2987
ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
* Development of Leptin receptor-based technology and hybrid LNP platform * Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential applications in CNS-targeted therapeutics * Technology validated by winning first place in...
2026-08-24 15:01
1649
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
* HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity * Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South...
2026-08-24 12:40
1731
Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease
NEW YORK, Aug. 23, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug Administ...
2026-08-24 11:05
1933
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innov...
2026-08-24 09:54
4307
CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed based o...
2026-08-21 20:08
16928
China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing renewed att...
2026-08-21 17:28
2003
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
NANJING, China, Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Op...
2026-08-21 17:20
2497
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23044
